Mar. 6 at 6:43 PM
Prenetics Global Limited announced a
$40 million share buyback program authorized by its board for the next 12 months, saying the move reflects management’s belief that the current stock price undervalues the business.
During Feb. 23–27, executives purchased about
$1.3 million in shares on the open market at an average price of around
$17.11, including roughly
$750,000 bought personally by CEO Danny Yeung. Combined with
$1.45 million purchased after the November 2025 earnings release, executives have invested about
$2.75 million of personal capital in company stock.
Prenetics reported about
$164 million in adjusted liquidity as of March 1 with no debt. Its premium health and longevity brand IM8 targets
$180–
$200 million in revenue in 2026 and adjusted EBITDA profitability by Q4 2027. The company also completed several strategic divestitures in 2025 and early 2026.
$PRE